1nhaler, a Scottish healthtech company developing a novel cardboard-based inhaler, has raised £2.2 million (approximately $2.8 million) in Series A follow-on funding to progress its lead product toward clinical testing and regulatory approval.
The funding round was led by Archangels, with participation from Scottish Enterprise and BBB Investments. According to the company, the capital injection marks a significant advancement in its development timeline, enabling the startup to move from the prototype and validation stages into human testing.
Advancing Toward Clinical Milestones
The proceeds will be deployed across several critical workstreams designed to bring 1inhaler’s single-dose cardboard inhaler to market. Planned uses include completing technical transfer to contract manufacturing partners, producing material specifically for clinical trials, conducting an early-stage clinical study, undertaking a manufacturing engineering study, and progressing commercial discussions with potential partners and customers.
Lisa McMyn, Co-founder and Chief Executive Officer at 1nhaler, commented on the milestone: “This investment takes us to one of the most important milestones in our journey – taking our own lead product into the clinic. The continued backing of Archangels, Scottish Enterprise and BBB Investments reflects the technical and commercial progress we have made over the past year.”
Scaling Manufacturing and Regulatory Strategy
The focus on manufacturing readiness suggests 1nhaler is preparing for the operational demands of clinical supply chains and eventual commercialisation. By engaging with contract manufacturers now and conducting dedicated engineering studies, the company is building the infrastructure necessary to support regulatory submissions with evidence of scalable, reproducible production processes.
The involvement of Scottish Enterprise, the national economic-development agency, indicates the startup has secured backing from both private investors and regional development bodies committed to growing Scotland’s life-sciences sector. BBB Investments, meanwhile, brings additional capital and potentially industry expertise to the syndicate.
European Context
1inhaler’s progression reflects broader momentum in European healthtech innovation, particularly within the medical-device subsector. The United Kingdom remains a significant hub for drug-delivery technologies and respiratory therapies, with startups increasingly securing institutional backing to bridge the gap between prototype development and clinical validation. The combination of private venture capital, regional development funding, and specialized healthcare investors has become a common financing model for UK-based medtech companies pursuing regulatory pathways in Europe and beyond.
As the European startup ecosystem continues to mature, Series A rounds of this scale for hardware-focused healthtech ventures demonstrate investor confidence in companies willing to undertake the longer development cycles and regulatory requirements inherent in medical-device innovation. 1inhaler’s funding round underscores the continuing appetite for capital-efficient solutions in respiratory care and drug delivery.